LLBO Lifeline Biotech Inc (CE)

SmallCapVoice.com, Inc. announces that a new audio interview featuring Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO), and its subsidiary, First Warning Systems�, Inc. is now available at SmallCapVoice.com. The interview can be heard here at http://smallcapvoice.com/llbo/llbo-10-13-08.php. SmallCapVoice.com is a corporate investor relations firm known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its client�s financial news releases. SmallCapVoice.com offers individual investors with the tools they need to make informed decisions about the stocks they are interested in. To learn more about SmallCapVoice.com, please visit http://www.smallcapvoice.com/services.html. About Lifeline Biotechnologies, Inc: Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System�, which is designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry billions of dollars annually, assuming the following are successfully completed: Clinical trials (if required) and filing and receiving a 510(k) from the FDA, and the product is successfully established in the marketplace. Lifeline competes in the money markets for funds to support the development of its product. The cost of funds, for early stage companies like Lifeline, are expensive and the terms have been, and may continue to be, dilutive. www.lbti.com Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, successful development of the Company�s product and regulatory and shareholder approval for anticipated actions.